首页> 外国专利> TARGETED THROMBOLYSIS FOR TREATMENT OF MICROVASCULAR THROMBOSIS

TARGETED THROMBOLYSIS FOR TREATMENT OF MICROVASCULAR THROMBOSIS

机译:靶向溶栓治疗微血管栓塞

摘要

The present invention provides fusion proteins for targeted delivery of plasminogen activators to platelet-VWF complexes, or alternatively to the site where these are located, in a fibrin- independent manner. The fusion protein of the invention are for use in methods for the prevention or treatment of diseases or conditions associated with such platelet-VWF complexes, which may cause microvascular thrombosis in diseases such as e.g. thrombotic thrombocytopenic purpura. Preferred targeting agents for incorporation into the fusion proteins are e.g. nanobodies against VWF or platelets. Preferred plasminogen activators for use in the fusion proteins comprise the protease domains of uPA or tPA. The invention further pertains to nucleic acid molecule encoding the fusion proteins of the invention, e.g. a gene therapy vector, and to pharmaceutical compositions comprising the fusion proteins of the invention or such gene therapy vectors.
机译:本发明提供了融合蛋白,以纤维蛋白非依赖性方式将纤溶酶原激活物靶向递送至血小板-VWF复合物,或选择性地递送至其定位的位点。本发明的融合蛋白用于预防或治疗与此类血小板-VWF复合物有关的疾病或病症的方法,所述疾病可能导致诸如例如丙型肝炎的微血管血栓形成。血栓性血小板减少性紫癜。用于掺入融合蛋白的优选的靶向剂是,例如。针对VWF或血小板的纳米抗体。用于融合蛋白的优选的纤溶酶原激活剂包括uPA或tPA的蛋白酶结构域。本发明进一步涉及编码本发明的融合蛋白的核酸分子,例如本发明的融合蛋白。基因治疗载体,以及包含本发明融合蛋白或此类基因治疗载体的药物组合物。

著录项

  • 公开/公告号CA3095080A1

    专利类型

  • 公开/公告日2019-10-03

    原文格式PDF

  • 申请/专利权人 UMC UTRECHT HOLDING B.V.;

    申请/专利号CA20193095080

  • 发明设计人 MAAS COEN;DE MAAT STEVEN;

    申请日2019-03-27

  • 分类号A61K38/16;A61K38/17;A61K38/49;A61P9/10;C07K14;C07K16;C07K19;

  • 国家 CA

  • 入库时间 2022-08-21 11:58:17

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号